Table 2.

BH3 mimetics in ALL treatment.

Drug	Preclinical Studies	Completed Clinical Studies	Ongoing Clinical Studies
Venetoclax	Venetoclax treatment of T-ALL 1 and ETP ALL 2 cell lines/blasts from patients [143] Venetoclax treatment of T-ALL cell lines/blasts from patients [144]	Series of cases, relapsing/remitting ALL 3 [145] Retrospective study, relapsing/remitting T-ALL [146] Phase I, relapsing/remitting ALL [147]	Phase Ib-II, navitoclax and venetoclax co-treatment for pre-transplant and post-transplant treatment of adult T-ALL patients (NCT05054465) Phase I, adult pre-B ALL 4 (NCT05157971) Phase I/phase II, relapsing/remitting ALL (NCT03808610, NCT03504644, NCT03576547, NCT03319901, NCT04872790, NCT05016947, NCT03808610, NCT04752163, and NCT05149378)
	Venetoclax and tofacitinib ex vivo co-treatment of JAK 5-mutated ALL cell lines and blasts from T-ALL patients [137]
Navitoclax	Navitoclax treatment of T-ALL and ETP ALL cell lines/blasts from patients [143]	Phase I, relapsing/remitting ALL [147]	Phase Ib-II, navitoclax and venetoclax co-treatment for pre-transplant and post-transplant treatment of adult T-ALL patients (NCT05054465)

¹ T-ALL, precursor T-cell acute lymphoblastic leukemia; ² ETP ALL, early T-cell progenitor acute lymphoblastic leukemia; ³ ALL, acute lymphoblastic leukemia; ⁴ pre-B ALL, precursor-B-cell acute lymphoblastic leukemia; ⁵ JAK, Janus kinases.